Ganoderma tRF-31 RNA Delivery for Asthma Airway Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current asthma treatments are inadequate, with many patients undiagnosed and untreated, and existing therapies fail to effectively address airway remodeling, leading to irreversible airflow limitation and poor response due to abnormal airway smooth muscle cell phenotypes.
Innovation Solution
Utilization of Ganoderma tRFs, specifically Ganoderma tRF_31, to inhibit airway remodeling by targeting and balancing the phenotype of airway smooth muscle cells, using them in drug formulations such as nasal drops or oral administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional asthma treatments are used, then patients may experience some symptom relief, but airway remodeling continues to progress leading to irreversible airflow limitation
Solution Approach 1:
The patent extracts and isolates specific microRNA molecules (miR-145, miR-143, miR-213) from Ganoderma that specifically target airway smooth muscle cell proliferation pathways. By extracting these active components rather than using whole Ganoderma extracts or traditional drugs, the invention achieves selective inhibition of airway remodeling while preserving other physiological functions.
Solution Approach 2:
The patent uses nanoparticles as intermediary carriers to deliver the Ganoderma microRNA molecules to target cells. These nanoparticles mediate the delivery process, protecting the microRNA from degradation and enabling targeted delivery to airway smooth muscle cells, thereby enhancing treatment effectiveness while reducing off-target effects.
2Reliability
If Ganoderma extracts are used for treatment, then anti-inflammatory and immunoregulatory effects are achieved, but anaphylactic reactions and toxicity may occur
Solution Approach 1:
The patent extracts only the specific microRNA molecules (miR-145, miR-143, miR-213) responsible for therapeutic effects from Ganoderma, separating them from proteins and other components that cause anaphylaxis and toxicity. This extraction eliminates harmful factors while retaining beneficial therapeutic activity.
Solution Approach 2:
The patent synthesizes artificial copies of the Ganoderma microRNA sequences in vitro. These synthetic microRNA molecules replicate the therapeutic function of natural Ganoderma microRNA without containing any protein components that could trigger allergic reactions, providing a safer therapeutic alternative.
3Stability of the object's composition
If airway smooth muscle cells are allowed to proliferate normally, then airway flexibility is maintained, but abnormal proliferation leads to airway remodeling and irreversible airflow limitation
Solution Approach 1:
The patent introduces exogenous microRNA molecules that provide negative feedback to the airway smooth muscle cell proliferation pathways. These microRNA molecules target and inhibit key signaling molecules involved in proliferation, creating a feedback mechanism that prevents abnormal cell growth while maintaining normal physiological function.
Solution Approach 2:
The patent changes the molecular parameter landscape within airway smooth muscle cells by introducing specific microRNA molecules that alter gene expression profiles. This changes the cellular phenotype from a proliferative state to a quiescent state, preventing airway remodeling while maintaining airway flexibility through regulated cell function.
Data Source
AI summary
A use of Ganoderma fungal RNA molecules, a drug, a drug composition and a delivery carrier are provided. It has been proved that the tRFs derived from the Ganoderma traditional Chinese medicine has an obvious inhibiting effect on airway smooth muscle cell phenotype change (proliferation, abnormal secretion and the like) induced by TGF-β1 and AHR, inflammation and remodeling of asthma mice induced by Dermatophagoides pteronyssinus in the experiments of the present disclosure, which suggests that the tRFs derived from the Ganoderma traditional Chinese medicine and a pharmaceutical composition can be a brand new medicine for treating asthma. The drug comprises the RNA molecule and a pharmaceutically acceptable carrier, diluent and/or excipient. The present disclosure is helpful for the research and development of asthma treatment drugs and provides reference for the research and development of other respiratory system disease treatment drugs.